Elamathi Natarajan

Elamathi Natarajan

Auto-generated profile, based on publicly available information

Elamathi Natarajan

Bioinformatics CRO Scientist, Biotecnika, Bangalore, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
PSPoulami Saha
Poulami Saha
ENElamathi Natarajan
Elamathi Natarajan
Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and neuronal death. A defining pathological hallmark of AD is the formation of intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Inhibiting the aggregation of this abnormal form of tau has emerged as a promising strategy for disease-modifying therapy. In this study, we designed a novel molecular scaffold combining 1,2,4-triazole and naphthalene moieties (TND), and developed ten structurally diverse derivatives (TND-1 to TND-10) by functionalizing various positions with electron-withdrawing and electron-donating substituents. These compounds were evaluated for their binding affinity against phosphorylated tau protein (PDB ID: 6HRF) using AutoDock Vina and further assessed for pharmacokinetic profiles using SwissADME. Docking scores ranged from −7.8 to −9.1 kcal/mol, indicating good binding potential. The top three compounds, TND-4, TND-6, and TND-9, demonstrated strong hydrogen bonding and π–π interactions with key active-site residues of the tau protein. ADMET predictions showed that most derivatives had favorable CNS penetration, high gastrointestinal absorption, and satisfied Lipinski’s rule of five, suggesting drug-likeness. These findings highlight the therapeutic promise of triazole–naphthalene derivatives in targeting tau pathology in AD. This study lays the groundwork for further lead optimization and experimental validation of these virtual candidates in future anti-Alzheimer’s drug discovery efforts.

6 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NANagendra
Nagendra
ENElamathi Natrajan
Elamathi Natrajan
NMNagendra Mannekunta
Nagendra Mannekunta
Background: Triple-negative breast cancer (TNBC) exhibits high molecular heterogeneity. While multi-omic panels capture disease complexity, translating these profiles into actionable, cost-effective prognostic tools remains analytically challenging. Objective: To mathematically distill a high-dimensional multi-omic profile into a lean, highly predictive biomarker panel. Furthermore, we aimed to construct, validate, and clinically anchor a prognostic survival nomogram. Methods: Matched TCGA-BRCA transcriptomic and epigenomic data (n=5546) were integrated utilizing MOFA2. Functional pathways were mapped via the Enrichr database against Reactome, KEGG, and WikiPathways libraries. A machine learning ensemble (LightGBM, Random Forest) optimized the discovery signature. Prognostic stability was validated via Kaplan-Meier stratification, continuous Z-score Multivariate Cox Regression, and Time-Dependent ROC modeling. The tumor microenvironment was profiled via ssGSEA, and immunotherapy checkpoint correlation was assessed. External validation was executed on a microarray cohort (GSE58812). Results: A 47-gene discovery signature was computationally optimized into a 15-gene clinical panel (Internal AUC = 0.9898). Kaplan-Meier analysis demonstrated profound prognostic separation (p < 0.0001). Multivariate Cox regression confirmed the signature’s independent prognostic value (Hazard Ratio = 10.67, p < 0.001). Immune profiling revealed the signature is driven by tumor-intrinsic factors, showing no significant correlation with local checkpoint expressions like PD-L1 (p = 0.72). External validation achieved an integrated multi-covariate AUC of 0.6874. Conclusion: This optimized 15-gene signature and the associated clinical-genomic nomogram provide an accurate, independent, and generalizable framework for individualized TNBC survival prediction.

19 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AZAman Zehra
Aman Zehra
ENElamathi Natarajan
Elamathi Natarajan
Inflammatory bowel disease (IBD) is associated with changes in gut microbiota composition and predicted microbial functions that may relate to intestinal immune processes. This study compared gut microbiota profiles between individuals with IBD and healthy controls and examined predicted microbial pathways and their associations with bacterial genera. Publicly available 16S rRNA amplicon sequencing data from 22 stool samples (11 IBD and 11 healthy controls) were analysed. Taxonomic profiling, diversity analysis, differential abundance testing, and PICRUSt2-based functional prediction were performed. Microbe–pathway associations were examined using Spearman correlation and Cytoscape. Extended analyses integrated differential abundance with machine-learning feature importance to prioritize candidate genera, evaluated a three-genus signature, assessed selected findings in an independent dataset, and compared predicted fermentation- and acetate-related pathways. Alpha diversity was significantly lower in the IBD group (Shannon index, p = 0.003), and Bray–Curtis PCoA showed separation of the two groups mainly along PC1 (PERMANOVA pseudo-F = 6.125, p < 0.001), although this separation may partly reflect differences between the source cohorts. DESeq2 identified 44 significantly differentially abundant genera among 186 tested (FDR-adjusted p < 0.05), of which 32 were lower and 12 were higher in the IBD group relative to healthy controls; 27 of these genera were detected in only one of the two groups. PICRUSt2 predicted lipopolysaccharide and peptidoglycan biosynthesis pathways; after normalising pathway abundances for sequencing depth, Spearman analysis identified 84 significant microbe–pathway associations, 47 with lipopolysaccharide biosynthesis (44 positive; ρ up to 0.90) and 37 with peptidoglycan biosynthesis (33 negative; ρ down to −0.82). Five genera were prioritized by integrated biomarker analysis. The combined three-genus signature achieved an ROC–AUC of 0.959. External validation was limited to Bifidobacterium, whose abundance direction was concordant with the discovery analysis. Of the two SCFA-related pathways examined, the predicted acetate-related pathway (methanogenesis from acetate) was lower in the IBD group (FDR = 0.002), whereas the predicted fermentation pathway did not differ significantly between groups (FDR = 0.076). These findings provide an integrated view of microbial composition and predicted functional potential in IBD. The small sample size, differences in cohort and sequencing characteristics between the IBD and control samples, limited external validation, and reliance on predicted rather than directly measured functions mean that the results are exploratory and require confirmation in larger independent cohorts and through direct functional or metabolomic analyses.

21 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMihika Vijay Kenavdekar
Mihika Vijay Kenavdekar
ENElamathi Natarajan
Elamathi Natarajan
The human gut microbiome plays a critical role in host health, yet its functional organization in disease remains poorly understood. Most studies focus on taxonomic composition or pathway abundance, which fail to capture higher-order interactions governing system-level behavior. Here, we investigated microbiome functional organization in inflammatory bowel disease (IBD), including Crohn’s disease (CD), ulcerative colitis (UC), and healthy controls (HC), using a network-based framework across 60 metagenomic samples. Functional pathway profiles were used to construct correlation-based interaction networks, followed by analysis of network topology, functional redundancy, keystone pathway architecture, and system robustness. Disease-associated networks (CD and UC) exhibited reduced global connectivity, increased modular fragmentation, and centralization of keystone pathways, indicating a shift from distributed organization to more fragmented and fragile network structures compared to healthy controls. Notably, machine learning models demonstrated that network-derived features achieved higher classification performance (accuracy up to 0.824) compared to redundancy-based measures. These findings reveal that microbiome dysfunction in IBD is driven by large-scale reorganization of functional interaction networks rather than loss of functional capacity. This study highlights the importance of network-level analysis in understanding microbiome-associated disease and provides a systems-level framework for future research.

13 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SJShabistan Jabin
Shabistan Jabin
ENElamathi Natarajan
Elamathi Natarajan
Background: RNA editing is a post-transcriptional modification that alters the sequence of an RNA transcript. Two types of RNA editing were found in mammals, involving the enzymatic deamination of either adenosine to inosine (A-to-I) or cytidine to uridine (C-to-U) nucleotides in RNA. A-to-I, which is the most common form of RNA editing, is mediated by the ADAR (adenosine deaminases acting on RNA) family of enzymes, ADAR1, ADAR2, and ADAR3. The editing event alters the hydrogen bond pairing of nucleobases, and the editing site will be recorded as guanosine rather than the original adenosine. Indeed, RNA editing deregulation has been linked to several nervous and neurodegenerative diseases. In this project work is done on Alzheimer’s disease (AD) and the samples are from anterior cingulate cortex of human brain tissue. AD is the main dementia in the world and a neurodegenerative condition prevalent in the elderly. Methodology: A total of 20 raw RNA-sequencing data samples containing 10 controls and 10 Alzheimer’s disease (AD) cases were collected from NCBI using SRA Toolkit. Quality assessment was performed using FastQC and processed using Trimmomatic. Alignment was done using STAR RNA-seq aligner. RNA editing detection was performed using REDItools, detected sites were subsequently annotated against the REDIportal database. The resulting control-specific and disease-specific novel editing sites were merged into a single dataset containing exclusively novel, group-specific A-to-I editing events. This merged dataset was subsequently used for downstream feature extraction and machine learning analysis. Probability-based filtering was done to extract high-confidence disease associated sites and their gene list was used for computational level biological validation, pathway and functional enrichment analysis as well as overlap with known AD loci. Results: Random Forest showed the highest accuracy score (0.804) and ROC-AUC score (0.854). Most important features that differentiated control and diseased novel sites in random forest were coverage (∼0.35), editing level (∼0.33) and GC content (∼0.15). The AEI mean values is higher in both male and female diseased cases (∼0.48-0.50) but less in male and female control cases (∼0.14-0.21). The mean values of ADAR1_CPM higher in control cases (123.65-143.30) and is less in diseased cases (88.35-97.93), ADAR2_CPM is almost equal in all cases (∼3.7-4.7) and ADAR3_CPM is very less in all the cases (∼0-0.02). Most candidate editing site were present in exon (∼62-67 %) CDS regions (∼17–21%) and relatively smaller fraction of gene (∼15-16 %). Editing alterations preferentially affect molecular systems governing synaptic structure, neurotransmission, and central nervous system integrity. In the main set -of the 2576 high-confidence genes identified, 33 overlapped with AD GWAS loci. In the core set -of the 1367 high-confidence genes identified, 11 overlapped with AD GWAS loci. Conclusion: Feature like coverage, editing level and GC content contributed most. Alu sites are negligible as compared to non-alu sites but the AEI mean values are higher in diseased cases than in control cases. The mean values of ADAR1_CPM are higher than ADAR2_CPM and ADAR3_CPM.Sex does not play a major factor. High-confidence disease-associated RNA editing sites are strongly biased toward transcript-centric regions, particularly exons, with a notable subset affecting coding sequences. Importantly, enrichment of neurodegeneration-associated pathways and cognition-related human phenotypes further supports the disease relevance of these gene networks. RNA editing events in Alzheimer’s cortex may represent a regulatory mechanism largely independent of inherited genetic susceptibility loci.

1 November 2026 in World Journal of Advanced Research and Reviews
Verified
Journal Article
Open access
AJAby John
Aby John
ENElamathi Natarajan
Elamathi Natarajan
HIV-1 is characterised by a high degree of genetic diversity, and it is this diversity that leads to resistance against antiretroviral drugs. Resistance occurs when changes in the viral genome reduce the virus's sensitivity to one or more of the antiretroviral agents. By identifying and predicting the mutations associated with resistance, clinicians and researchers are able to explain why treatment fails, monitor the way in which the virus evolves, and select appropriate treatment regimens. Traditional genotypic interpretation makes use of established mutation patterns and scoring systems in order to estimate susceptibility. More recently, progress in the fields of bioinformatics and machine learning has expanded the range of methods available for deducing resistance from viral sequences, the methods extending from statistical regression and support vector machines to random forests, gradient boosting and deep neural networks. Resources that are openly available, especially the Stanford HIV Drug Resistance Database, provide paired genotype and phenotype records which enable model building and benchmarking. Yet, despite this, it is still very difficult to make reliable predictions, due to the diversity of viruses, the effect of interacting mutations, imbalanced class distributions, inconsistent definitions of resistance, and the lack of independently validated data. This review addresses the biology of HIV drug resistance, the existing interpretation tools, computational prediction methods, evaluation practices, and the open problems, and looks at how interpretable and widely applicable systems might be developed. The use of computational models together with established interpretation systems and appropriate clinical evidence could make resistance assessment more reliable.